Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286960222> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W4286960222 endingPage "1404" @default.
- W4286960222 startingPage "1398" @default.
- W4286960222 abstract "Recently, neoadjuvant treatment approach has gained importance in locally advanced HER-2 positive breast cancer. Adding pertuzumab increases pathological complete response (pCR). In this study, we aimed to examine the clinicopathologic features that predict the pCR in patients receiving neoadjuvant pertuzumab, trastuzumab, and chemotherapy in locally advanced HER2 positive breast cancer.Locally advanced HER2 positive breast cancer patients who were followed up in 4 different oncology centers and received 4 cycles of pertuzumab, trastuzumab and taxane were retrospectively evaluated. A total of 58 (92%) patients received anthracycline chemotherapy before combination of dual her-2 blockade and taxanes. Fisher's and chi-square tests were used for nominal variables and numeric data analyses.A total of 63 female patients were included in the study. Their median age was 46 years (21-75) and 40 (63.5%) patients were premenopausal. Median tumor size was 25 mm (2-70) and there were 22 (34.9%) patients with Stage 3a. pCR was 66% and 75% in the whole group and in the hormone negative group, respectively. Statistically significant increase was found in pCR in patients with grade 3 tumors and cerbB2 with 3+ immunohistochemical staining. No relationship was found between pCR and age at diagnosis, menopausal status, tumor infiltrating lymphocyte, dose-dense anthracycline, Ki67≥40, body mass index (BMI) ≥ 30 kg/m2 and accompanying DCIS.Four cycles of pertuzumab, trastuzumab and taxane after neoadjuvant anthracycline for locally advanced HER2 breast cancer are associated with increased pCR in patients with grade 3 tumors and high cerbB2 expression." @default.
- W4286960222 created "2022-07-25" @default.
- W4286960222 creator A5001724116 @default.
- W4286960222 creator A5011701013 @default.
- W4286960222 creator A5013967282 @default.
- W4286960222 creator A5033348156 @default.
- W4286960222 creator A5033820961 @default.
- W4286960222 creator A5043458305 @default.
- W4286960222 creator A5047090646 @default.
- W4286960222 creator A5052748672 @default.
- W4286960222 creator A5059549179 @default.
- W4286960222 creator A5065430193 @default.
- W4286960222 creator A5075032325 @default.
- W4286960222 date "2021-09-27" @default.
- W4286960222 modified "2023-09-27" @default.
- W4286960222 title "Evaluation of factors predicting pathologic complete response in locally advanced HER2 positive breast cancer treated with neoadjuvant pertuzumab, trastuzumab and chemotherapy; Real life data." @default.
- W4286960222 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34564997" @default.
- W4286960222 hasPublicationYear "2021" @default.
- W4286960222 type Work @default.
- W4286960222 citedByCount "1" @default.
- W4286960222 countsByYear W42869602222023 @default.
- W4286960222 crossrefType "journal-article" @default.
- W4286960222 hasAuthorship W4286960222A5001724116 @default.
- W4286960222 hasAuthorship W4286960222A5011701013 @default.
- W4286960222 hasAuthorship W4286960222A5013967282 @default.
- W4286960222 hasAuthorship W4286960222A5033348156 @default.
- W4286960222 hasAuthorship W4286960222A5033820961 @default.
- W4286960222 hasAuthorship W4286960222A5043458305 @default.
- W4286960222 hasAuthorship W4286960222A5047090646 @default.
- W4286960222 hasAuthorship W4286960222A5052748672 @default.
- W4286960222 hasAuthorship W4286960222A5059549179 @default.
- W4286960222 hasAuthorship W4286960222A5065430193 @default.
- W4286960222 hasAuthorship W4286960222A5075032325 @default.
- W4286960222 hasConcept C121608353 @default.
- W4286960222 hasConcept C126322002 @default.
- W4286960222 hasConcept C143998085 @default.
- W4286960222 hasConcept C146357865 @default.
- W4286960222 hasConcept C151730666 @default.
- W4286960222 hasConcept C2776694085 @default.
- W4286960222 hasConcept C2776802502 @default.
- W4286960222 hasConcept C2777511904 @default.
- W4286960222 hasConcept C2778292576 @default.
- W4286960222 hasConcept C2779786085 @default.
- W4286960222 hasConcept C2781164504 @default.
- W4286960222 hasConcept C530470458 @default.
- W4286960222 hasConcept C71924100 @default.
- W4286960222 hasConcept C86803240 @default.
- W4286960222 hasConceptScore W4286960222C121608353 @default.
- W4286960222 hasConceptScore W4286960222C126322002 @default.
- W4286960222 hasConceptScore W4286960222C143998085 @default.
- W4286960222 hasConceptScore W4286960222C146357865 @default.
- W4286960222 hasConceptScore W4286960222C151730666 @default.
- W4286960222 hasConceptScore W4286960222C2776694085 @default.
- W4286960222 hasConceptScore W4286960222C2776802502 @default.
- W4286960222 hasConceptScore W4286960222C2777511904 @default.
- W4286960222 hasConceptScore W4286960222C2778292576 @default.
- W4286960222 hasConceptScore W4286960222C2779786085 @default.
- W4286960222 hasConceptScore W4286960222C2781164504 @default.
- W4286960222 hasConceptScore W4286960222C530470458 @default.
- W4286960222 hasConceptScore W4286960222C71924100 @default.
- W4286960222 hasConceptScore W4286960222C86803240 @default.
- W4286960222 hasIssue "4" @default.
- W4286960222 hasLocation W42869602221 @default.
- W4286960222 hasOpenAccess W4286960222 @default.
- W4286960222 hasPrimaryLocation W42869602221 @default.
- W4286960222 hasRelatedWork W10233532 @default.
- W4286960222 hasRelatedWork W14333088 @default.
- W4286960222 hasRelatedWork W15852517 @default.
- W4286960222 hasRelatedWork W16909223 @default.
- W4286960222 hasRelatedWork W1852032 @default.
- W4286960222 hasRelatedWork W2337926 @default.
- W4286960222 hasRelatedWork W2422317 @default.
- W4286960222 hasRelatedWork W5038423 @default.
- W4286960222 hasRelatedWork W5387012 @default.
- W4286960222 hasRelatedWork W19634549 @default.
- W4286960222 hasVolume "26" @default.
- W4286960222 isParatext "false" @default.
- W4286960222 isRetracted "false" @default.
- W4286960222 workType "article" @default.